Wound Center Biologics Evaluation Checklist

Wound Center Biologics Evaluation Checklist

A value analysis committee that picks a biologic on unit price alone is not saving money. It is outsourcing the risk to the next quarterly review.

The CMS 2026 skin-substitute payment restructuring made this plain. With a flat national rate of $127.14 per square centimeter and Local Coverage Determinations withdrawn, margin is tighter and evidence matters more, not less. A lower acquisition cost can mask a higher total cost of care: more applications, slower closure, more clinic visits, and downstream admissions.

This checklist is designed for wound center value analysis committees, supply-chain managers, and clinic administrators who need a structured, defensible way to evaluate biologic allograft products. It covers eight domains: clinical evidence, product handling and storage, supply chain reliability, reimbursement support, payer mix considerations, staff training, total cost-of-use modeling, and post-implementation monitoring. A one-page downloadable PDF version is available at the end of this article.

> Disclaimer: This checklist is for educational and organizational use only. It does not replace institutional procurement policies, clinical judgment, or legal and regulatory advice. Verify all coverage, coding, and compliance requirements with your Medicare Administrative Contractor, commercial payers, and institutional compliance officers before making formulary decisions.

---

1. Clinical Evidence Criteria

The first question is not whether the product works somewhere. It is whether it works in the wound types your center treats most often.

RCTs and systematic reviews

- Does the product have published randomized controlled trials (RCTs) in your target wound type — diabetic foot ulcer, venous leg ulcer, pressure injury, or surgical wound? - Are those RCTs peer-reviewed, with complete wound closure at a defined endpoint as a primary or co-primary outcome? - Has a meta-analysis or systematic review evaluated the product or the product category? - Do the studies compare the product plus standard of care against standard of care alone, or against an active comparator relevant to your formulary?

Real-world data

- Are there prospective cohort studies, patient registries, or large retrospective analyses in wound types matching your census? - Does the manufacturer provide audited real-world evidence, or only unpublished case summaries?

Indication match

- Is the product cleared or marketed for the wound types you treat? - Does the manufacturer’s intended use align with your patient severity mix (e.g., Wagner grade, wound size, comorbidities)? - Is the published evidence product-specific, or are claims extrapolated from a broader category?

A product with Level I evidence in diabetic foot ulcer may carry no evidence at all in venous leg ulcer. Evidence is not transferable across indications.

---

2. Product Handling and Storage

Logistics determine whether a product is usable in your facility, not just whether it is clinically sound.

Format and preparation

- Is the product cryopreserved, dehydrated, micronized, or sheet form? - Does it require rehydration, thawing, or other preparation before application? - What is the shelf life after opening? After reconstitution? - What is the sterility claim and expiration dating?

Storage requirements

- Cryopreserved products require ultralow-temperature freezers (−60°C to −80°C), continuous temperature monitoring, validated alarms, and documented thawing protocols. - Dehydrated or ambient products require controlled room temperature (15–30°C), protection from moisture, and inventory rotation. - Does your facility already have the infrastructure, or must it be purchased, maintained, and validated?

Handling and waste risk

- How fragile is the product during preparation and transfer? - What is the documented waste rate from damaged units, improper thawing, or expired inventory?

---

3. Supply Chain Reliability

A product that closes wounds faster is irrelevant if it is not on the shelf when the patient is ready.

- What is the standard lead time from order to delivery? - Can the vendor provide 12 months of on-time delivery data? - What has been the backorder frequency and duration in the last 24 months, and what were the root causes? - Does the product require cold-chain shipping? Is the cold chain validated door-to-door? - What is the single-source risk? Does the manufacturer operate one facility, or are there redundant production sites? - What is the vendor’s contingency plan for recall, supply interruption, or natural disaster?

---

4. Reimbursement Support and Coding Alignment

Coverage and payment are not the same thing. A product may be billable and still be denied.

Coding

- What is the HCPCS code and CPT application code set for the product and its intended use setting? - Does the vendor provide a coding reference and application guidance? - Is the product classified under Section 361 HCT/P, Section 351 biologic, 510(k) device, or another pathway?

Payer coverage

- Which Medicare Administrative Contractors or commercial payers cover the product for your target wound types under reasonable-and-necessary criteria? - What is the prior-authorization burden, including denial rates and appeal success rates? - Does the vendor provide dedicated reimbursement support, including prior-auth submission and appeals assistance? - Is the vendor’s documentation support aligned with your local coverage policies?

---

5. Payer Mix Considerations

Your center’s financial exposure depends on who pays for the patients you see.

- What percentage of your biologic-eligible patients are Medicare fee-for-service, Medicare Advantage, Medicaid, commercial, or self-pay? - Does the product have predictable coverage under each payer category, or is it concentrated in one segment? - Are there managed-care contracts that limit product choice or require step therapy? - What is the patient cost-sharing burden, and how does it affect adherence to the treatment plan? - Does the product’s reimbursement profile align with your center’s risk-sharing or bundled-payment arrangements?

A product that is well-covered under traditional Medicare but routinely denied by the Medicare Advantage plans common in your market may be the wrong formulary choice, even if the clinical evidence is strong.

---

6. Staff Training and Clinical Support

A biologic is only as effective as the team applying it.

- What training does the manufacturer provide for physicians, nurses, and clinical staff? - Is training available on-site, virtual, or on-demand? - Are there application technique guides, video resources, and competency checklists? - Does the manufacturer provide clinical support for complex cases, adverse events, or troubleshooting? - Is there a dedicated clinical liaison or account support structure? - What is the process for reporting product complaints, adverse events, and MedWatch submissions?

Training is a cost, but it is also a risk-mitigation tool. Poor application technique can negate the clinical evidence that supported formulary approval.

---

7. Total Cost-of-Use Modeling

Unit price is the least informative number in a value analysis. The useful number is total cost of use.

Direct costs

- Unit acquisition cost per application - Number of applications typically required to closure - Application procedure costs, including facility time, supplies, and secondary dressings - Storage infrastructure costs, including capital equipment, monitoring, and maintenance - Staff training and competency validation costs

Indirect costs

- Cost of delayed closure, including additional visits, dressing changes, and labor - Risk of hospitalization, amputation, or readmission if closure is prolonged - Cost of waste, expired inventory, or failed applications - Administrative burden from prior authorizations, denials, and appeals

A simple cost-per-closure model is:

> Cost per closure = (average applications × unit cost) + (average visits × facility overhead per visit)

A product with a higher unit price but fewer applications and lower overhead can easily produce a lower cost per closure than a cheaper alternative.

---

8. Post-Implementation Monitoring

Formulary approval is the start of evaluation, not the end.

- Is there a defined protocol to track outcomes: wound type, baseline severity, product applied, number of applications, time to closure, adverse events, and total episode cost? - Who is the designated clinical lead for adverse event reporting and product complaints? - How often will the committee review outcomes against the claims that supported approval? - When will contracts be reviewed, and what evidence or pricing changes would trigger formulary reconsideration?

Products should not stay on formulary by inertia. A product approved in 2026 should be re-evaluated if new evidence, new pricing, or new coverage policies change its value profile.

---

Download the Checklist

The framework above is summarized in a one-page PDF checklist designed for committee use.

Use it as a starting point and adapt it to your institutional procurement policies, payer environment, and formulary workflow.

---

Closing

The wound center biologics market is crowded with products that look similar on a price sheet. The committees that distinguish them do so by treating procurement as a clinical and operational risk decision, not a purchasing exercise.

Evidence, handling, supply chain, reimbursement, payer mix, training, and total cost-of-use are not separate questions. They are dimensions of the same question: does this product close wounds reliably in your facility, for your patients, under your economic constraints?

That is the question this checklist is built to answer.

---